Altor BioScience clinical trials
Acquired by ImmunityBio, Inc., Mar 9, 2021 · source ↗
The registry lists 15 studies whose lead sponsor is Altor BioScience. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 10, 2026.
Before and after it joined ImmunityBio, Inc.
- First submitted before Altor BioScience became part of ImmunityBio, Inc.
- 15
- First submitted after Altor BioScience became part of ImmunityBio, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Altor BioScience15 studies
Something wrong with this grouping? Tell us on the ImmunityBio, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 15 of 15. All ImmunityBio, Inc. studies →
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaTerminatedNCT01029873Phase 1/2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803CompletedNCT03381586Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid TumorsCompletedNCT01946789Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress SyndromeCompletedNCT01438853Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)TerminatedNCT04142359
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02099539Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerTerminatedNCT01625260Phase 1/2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabTerminatedNCT02384954Phase 1/2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerCompletedNCT01326871Phase 1/2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01670994Phase 1/2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-PaclitaxelCompletedNCT02559674Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid TumorsCompletedNCT01325558Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress SyndromeCompletedNCT00879606Phase 2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnNCT01478074Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesCompletedNCT00496860Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.